PT  - JOURNAL ARTICLE
AU  - Glenardi, Glenardi
AU  - Handayani, Tutwuri
AU  - Barus, Jimmy
AU  - Mangkuliguna, Ghea
TI  - Inhaled Levodopa (CVT-301) for the Treatment of Parkinson Disease
AID  - 10.1212/CPJ.0000000000001143
DP  - 2022 Apr 01
TA  - Neurology: Clinical Practice
PG  - 139--148
VI  - 12
IP  - 2
4099  - http://cp.neurology.org/content/12/2/139.short
4100  - http://cp.neurology.org/content/12/2/139.full
AB  - Purpose of Review To investigate the efficacy and safety of CVT-301 in treating motor fluctuation in patients with Parkinson disease (PD).Recent Findings This study demonstrated that the CVT-301 group had a higher proportion of patients achieving an ON state than the placebo group (odds ratio [OR] = 2.68; 95% confidence interval [CI]: 1.86–3.86; p < 0.00001). Moreover, CVT-301 had also shown to improve motor function by Unified Parkinson Disease Rating Scale part III score (standardized mean difference = 3.83; 95% CI: 2.44–5.23; p < 0.00001) and promote an overall improvement of PD by Patient Global Impression of Change self-rating (OR = 2.95; 95% CI: 1.78–4.9; p < 0.00001). The most common adverse events encountered were respiratory symptoms (OR = 12.18; 95% CI: 5.01–29.62; p < 0.00001) and nausea (OR = 3.95; 95% CI: 1.01–15.41; p = 0.05).Summary CVT-301 had the potential to be an alternative or even a preferred treatment for motor fluctuation in patients with PD.